Existing treatments pulmonary arterial hypertension (PAH) widen blood vessels, can help relieve symptoms and extend life, but cannot cure the disease or repair the damaged vessels. The field is now moving toward treatments that could actually modify the underlying disease process, based on promising laboratory research that’s being tested in patients. Two important breakthroughs include the approval of sotatercept—the first drug believed to target the structural damage in blood vessels—and the development of seralutinib, an inhaled medication that blocks specific cellular signals involved in the disease.
A review published in the Trends in Pharmaceutical Science journal In this review, focuses on anti-remodeling therapies that have progressed from preclinical models to clinical trials. These include agents targeting cell cycle regulators, kinase pathways, epigenetic modifiers, bone morphogenetic protein receptor type 2 (BMPR2) signaling, and senescence in pulmonary arterial smooth muscle cells (PASMCs), offering renewed hope for durable pulmonary arterial hypertension treatment.
Read more at this link on the Trends in Pharmaceutical Science (abstract only, full access only on request)
Citation
Boucherat O, Bonnet S, Provencher S, Potus F. Anti-remodeling therapies in pulmonary arterial hypertension. Trends Pharmacol Sci. 2025 Jun 19:S0165-6147(25)00094-X. doi: 10.1016/j.tips.2025.05.004. Epub ahead of print. PMID: 40541519.
